Vyome Secures Exclusive License for JAK Inhibitors, Targeting $57B Market
Event summary
- Vyome Holdings has signed an agreement with Impetis Biosciences for exclusive rights to develop and commercialize selective JAK 1/3 and JAK1 inhibitors.
- The deal opens access to a $57B market opportunity within the broader $430B immuno-inflammatory market by 2034.
- Vyome will develop the assets through non-dilutive pathways, maintaining focus on its lead asset VT-1953 for malignant fungating wounds.
- Impetis, a TATA Enterprise, brings preclinical data showing differentiation from older-generation JAK inhibitors.
The big picture
Vyome's deal with Impetis underscores the growing demand for selective JAK inhibitors, which address safety concerns tied to older-generation drugs. The agreement also highlights the strategic value of the US-India innovation corridor in biotech, where capital-efficient licensing deals are becoming a key growth driver. With the JAK inhibitor market projected to reach $57B by 2030, Vyome is positioning itself to capture a significant share of this expanding segment.
What we're watching
- Execution Risk
- Whether Vyome can successfully transition Impetis' preclinical assets into clinical development without diluting capital.
- Market Dynamics
- How selective JAK inhibitors will compete against older-generation drugs amid FDA warnings about safety risks.
- Strategic Expansion
- The pace at which Vyome diversifies beyond its core focus on VT-1953 into broader immuno-inflammatory therapeutic areas.
Related topics